Revenue ($USD) : $399,245,000
R&D spend : $73,915,000
Employees : 1,200
Fiscal year end : 12/31/2023
CEO : Michael Carrel

www.atricure.com

AtriCure develops devices for atrial fibrillation (AFib) and related conditions. AtriCure has carved out a strong niche in the surgical space, holding a significant share of the left atrial appendage (LAA) market with its AtriClip LAA exclusion system, which received regulatory approval in China in 2024. AtriCure also offers the Isolator Synergy ablation clamp for treating AFib and the Hybrid AF therapy for AFib, along with cryoablation technology. –SW